Abstract
Breast cancer is the most common cancer in women worldwide. Minimally invasive percutaneous image-guided biopsies are the current cornerstone in the diagnosis of breast lesions detected on mammography/ultrasonography/MRI or palpable clinically. However, apparently benign breast disease seen on benign biopsies is a limiting factor for diagnosis and a risk factor of breast cancer especially in the high-risk category patients. Hypothesizing that molecular changes often occur before morphological variations, the levels of the LncRNA H19 were measured in anonymous tissues obtained from 79 women’s image guided breast biopsies, and correlated with cancer progression and aggressiveness. Using a double-blinded approach, H19 might be attributed an interesting role of a more sensitive biomarker in core breast biopsies, independently of the radiological/clinical classification and distant from the clinical management. We established different thresholds for H19 levels in normal versus proliferative, versus malignant tissues. Additionnally, H19 could act as an intra-group risk marker categorizing the biopsies in normal versus benign, versus precancerous breast tissue, and as a prognostic factor in cancerous lesions discriminating aggressive versus nonaggressive lesions. Our study suggests that the lncRNA H19 could be a potential marker for breast cancer diagnosis, prognosis and risk management.
Highlights
Breast cancer is the most common cancer in women worldwide
Our results showed that the long noncoding RNA H19 measured in fresh breast biopsies could be a potential marker for cancer diagnosis, and a good marker for subcatecorizing the lesions
A better understanding of the molecular biology of breast cancer added to a better characterization of the known and newly discovered potential markers, would be of importance for the care and treatment of breast cancer
Summary
Invasive percutaneous image-guided biopsies are the current cornerstone in the diagnosis of breast lesions detected on mammography/ultrasonography/MRI or palpable clinically. Interval cancers occur in the age-specific screening group during the interval between two consequent screenings They are characterized by very aggressive tumors with rapid grow[4]. Percutaneous image guided biopsies are the cornerstone of histological d iagnosis[6] They replace surgical diagnostic biopsies for the majority of breast lesions[7]. To be able to characterize the lesion histologically and to plan overall oncological management for very large cancers, needle biopsy is performed. It allows the identification of the histological type and grade, basal subtype, hormonal and HER2 receptor status, as well as genetic profiling[5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
